Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 3;12(5):1300-10.
doi: 10.1080/21645515.2015.1136040. Epub 2016 Feb 1.

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

Roger Baxter  1 , Pavitra Keshavan  2 , Jo Anne Welsch  3 , Linda Han  3 , Igor Smolenov  2
Affiliations
Review

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

Roger Baxter et al. Hum Vaccin Immunother. .

Abstract

Persistence of bactericidal antibodies following vaccination is extremely important for protection against invasive meningococcal disease, given the epidemiology and rapid progression of meningococcal infection. We present an analysis of antibody persistence and booster response to MenACWY-CRM, in adolescents, children and infants, from 7 clinical studies. Immunogenicity was assessed using the serum bactericidal assay with both human and rabbit complement. Post-vaccination hSBA titers were high, with an age- and serogroup-specific decline in titers up to 1 y and stable levels up to 5 y The waning of hSBA titers over time was more pronounced among infants and toddlers and the greatest for serogroup A. However, rSBA titers against serogroup A were consistently higher and showed little decline over time, suggesting that protection against this serogroup may be sustained. A single booster dose of MenACWY-CRM administered at 3 to 5 y induced a robust immune response in all age groups.

Keywords: MenACWY-CRM; booster; hSBA; meningococcal; persistence; rSBA.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentages of subjects with SBA titers ≥8 and 95% CIs (error bars) at baseline (pre-vaccination), and 1 month and 1 y after 1 dose of MenACWY-CRM given to adolescents (11–18 y at time of vaccination; Study 1) and children (2–5 and 6–10 y at time of vaccination; Study 2), by serogroup.
Figure 2.
Figure 2.
Percentages of subjects with SBA titers ≥8 and 95% CIs (error bars) at baseline (pre-vaccination), 1 month, and 5 y after 1 dose of MenACWY-CRM given to adolescents (11–18 y of age at the time of vaccination; Study 3) and children (2–5 and 6–10 y at the time of vaccination; Study 4), by serogroup.
Figure 3.
Figure 3.
Percentages of subjects with hSBA titers ≥8 and 95% CIs (error bars) at baseline (pre-vaccination) and 1 month and 6 months after 3 doses of MenACWY-CRM given to infants at 2, 4, and 6 months of age (Study 6), and at 1 month and ∼7 months after 2 doses of MenACWY-CRM given to toddlers at 6–8 months and 12 months of age (Study 5), by serogroup.
Figure 4.
Figure 4.
Percentages of subjects with hSBA titers ≥8 and 95% CIs (error bars) at 40 months and 60 months of age (Study 7), after either 4 doses (given at 2, 4, 6 and 12/13 months of age) or 2 doses (given at 12/13 and 15 months of age) of MenACWY-CRM given to infants in Study 3, by serogroup.
Figure 5.
Figure 5.
Percentages of subjects with rSBA titers ≥8 and 95% CIs (error bars) at 40 months and 60 months of age (Study 7), after either 4 doses (given at 2, 4, 6 and 12/13 months of age) or 2 doses (given at 12/13 and 15 months of age) of MenACWY-CRM given to infants in Study 3, by serogroup.
Figure 6.
Figure 6.
Percentages of subjects with hSBA titers ≥8 and 95% CIs (error bars) pre-booster and at 1 month after booster dose of MenACWY-CRM given 3 y after a single primary dose of MenACWY-CRM in adolescents aged 11–18 y (Study 3) or 5 y after a single dose in children aged 2–5 and 6–10 y of age (Study 4), or 5 y after 2-dose primary vaccination series in toddlers 12–24 months of age or 4-dose primary series in infants aged 2 months (Study 7), by serogroup.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 Suppl 2:B51-863; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063 - DOI - PubMed
    1. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057; http://dx.doi.org/10.1016/S1473-3099(10)70251-6 - DOI - PubMed
    1. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention (CDC) . Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendations Rep March 2013. 66(RR02);1-22 [accessed November2015]. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm - PubMed
    1. National Health Service, UK The NHS vaccination schedule, April 2014. [accessed November2015]. Available at: http://www.nhs.uk/Conditions/vaccinations/Pages/vaccination-schedule-age...
    1. Departamento de Actualización Profesional Boletín Official 33.085, 12 March 2015. [accessed November2015] Available at http://www.colfarsfe.org.ar/newsfiles/marzo2015/Disposiciones12-03-15.pdf

MeSH terms

LinkOut - more resources